We are live on ! Find out more
MAIA icon

MAIA Biotechnology
MAIA

6 hedge funds and large institutions have $1.04M invested in MAIA Biotechnology in 2022 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

281% more capital inflows, than outflows

Capital inflows: $314K | Capital outflows: $82.4K

100% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 1

0.6% more ownership

Funds ownership: 2.11% → 2.71% (+0.6%)

33% less funds holding

Funds holding: 9 → 6 (-3)

60% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 5

Holders
6
Holders Change
-3
Holders Change %
-33.33%
% of All Funds
0.1%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
2
Reduced
1
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Lynwood Capital Management
Lynwood Capital Management
Ontario, Canada
+$174K
2
Centric Wealth Management
Centric Wealth Management
Illinois
+$139K
3
BlackRock
BlackRock
New York
+$1.04K
4
Bank of America
Bank of America
North Carolina
+$7

Top Sellers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
-$39K
2
Jane Street
Jane Street
New York
-$34K
3
UBS Group
UBS Group
Switzerland
-$5.39K
4
OIA
Optimum Investment Advisors
Illinois
-$3K
5
Tower Research Capital (TRC)
Tower Research Capital (TRC)
New York
-$1K

MAIA Hedge Fund Activity: Q4 2022 in Review

6 of the 6,243 institutional investors tracked by Wall St. Rank reported a position in MAIA Biotechnology (MAIA) for Q4 2022, worth a combined $1.04M — up 37% from $763K a quarter earlier.

Sellers outnumbered buyers: 5 funds closed out of MAIA and 2 opened new positions — a net loss of 3 holders — while 1 trimmed existing stakes and 2 added.

The largest buyer was Lynwood Capital Management, adding an estimated $174K. The largest seller was Millennium Management, exiting entirely with an estimated $39K sold.

  • 6 institutional investors held MAIA Biotechnology (MAIA) as of Q4 2022, down from 9 in Q3 2022.
  • Funds reported $1.04M of MAIA Biotechnology stock for Q4 2022, up 37% quarter-over-quarter.
  • 2 funds opened new MAIA Biotechnology positions in Q4 2022 and 5 closed out, a net change of -3 holders.
  • The largest MAIA Biotechnology buyer in Q4 2022 was Lynwood Capital Management, an estimated $174K added.
  • The largest MAIA Biotechnology seller in Q4 2022 was Millennium Management, an estimated $39K sold.

Based on aggregated 13F filings for Q4 2022.